DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 17-911/S-065

Merck Research Laboratories
Sumneytown Pike
P.O.Box 4, BLA-20
West point, PA 19486

Attention: Kenneth A. Kramer
Manager, regulatory Affairs

Dear Mr. Kramer:

Please refer to your supplemental new drug application dated April 1, 1998, received April 2, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Clinoril (sulindac) Tablets.

We acknowledge receipt of your submissions dated January 17, 2003, and May 10, 2005. Your submission of May 10, 2005, constituted a complete response to our May 22, 2003, action letter.

This supplemental new drug application provides for revisions to the **CLINICAL PHARMACOLOGY** section of the package insert.

We have completed our review of this application, as amended, and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA.* Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 17-911/S-065**." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Allison Meyer, Regulatory Project Manager, at (301) 796-1258.

Sincerely,

{See appended electronic signature page}

Bob Rappaport, M.D.
Director
Division of Anesthesia, Analgesia and
Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Bob Rappaport

10/5/2006 07:13:43 PM